Results 161 to 170 of about 83,254 (357)

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson, Linda Stein Gold, Seemal R. Desai, Alexandra K. Golant, Douglas DiRuggiero, Christian Fenske, Yolanda Muñoz Maldonado, Alvin H. Li, Zach Dawson, Kaylee Ho, Kayla Callahan, Gaia Gallo, Jonathan I. Silverberg   +12 more
wiley   +1 more source

Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

, 2016
Eugene Guorong Yang, Nurulhuda Mustafa, Eng Chong Tan, Anders Poulsen, Pondy Murugappan Ramanujulu, Wee Joo Chng, J. J. Yen, Brian Dymock   +7 more
openalex   +1 more source

Successful Treatment of Paediatric Necrobiosis Lipoidica With Baricitinib

JEADV Clinical Practice, EarlyView.
ABSTRACT Necrobiosis lipoidica (NL) is a rare, chronic granulomatous condition that typically presents as sharply demarcated plaques with telangiectasia and atrophic centres. Paediatric cases are uncommon, and treatment options often fail to address refractory cases.
P. Simões Farinha, M. J. Paiva‐Lopes
wiley   +1 more source

Janus kinase inhibitors clear to land [PDF]

Rheumatology, 2017
openaire   +2 more sources

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

JEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson, Kara Hurley, Hannah Chaudhury, Lara Shehadeh, Cameron West   +4 more
wiley   +1 more source

Treatment of discoid lupus erythematosus scarring alopecia with deucravacitinib: A case report

SAGE Open Medical Case Reports
Discoid lupus erythematosus is a chronic, recurring, autoimmune skin disease causing annular, scarring plaques on the head and neck. Deucravacitinib, a tyrosine kinase 2 inhibitor in the Janus kinase inhibitor family, represents an emerging treatment ...
Katherine Aw, Genevieve Gavigan
doaj   +1 more source

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. [PDF]

, 2015
ObjectiveTofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The pathways affected by tofacitinib and the effects on gene expression in situ are unknown.
Boyle, DL, Bradley, J, Firestein, GS, Hodge, J, Kaplan, I, Kavanaugh, A, Krishnaswami, S, Luo, Z, Mandel, D, Mease, P, Rosengren, S, Shurmur, R, Singhal, AK, Soma, K, Wei, N   +14 more
core  

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

Janus Kinase Inhibitors in the Treatment of Alopecia Areata [PDF]

, 2023
Athanasios J Stefanis
openalex   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
wiley   +1 more source